An FDA Green Light Could Be in this Underfollowed Biotech Company's Future!

This Undiscovered Biotech Has Blockbuster Potential... This Undiscovered Biotech Has Blockbuster Potential...                                                                                                      You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. This message is from Smallcaps Daily. --------------------------------------------------------------- [This first-in-classbiotechnology company with the world’s ONLY fully human anti-CD3 monoclonal antibody in clinical development should be high on your radar!]( There is currently still no cure for neurodegenerative diseases such as Alzheimer's, MS, and ALS. The rise in diagnoses can be attributed to the aging population as life expectancy increases. Not only is this a growing health concern, but the annual cost to the US from Alzheimer’s disease and related dementias and other neurodegenerative diseases is tremendous. It was $655 billion in 2020! Now more than ever we need treatments to fight these terrible diseases. One underfollowed NASDAQ company in the biotech space is uniquely standing out as it focuses on developing drugs with a unique approach for these rising diseases. This clinical-stage biotechnology company specializes in developing transformative therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, Crohn's Disease and KRAS NSCLC. The company’s “wonder drug” is the world’s only fully human anti-CD3 monoclonal antibody in clinical development! Activated T cells play an important role in the inflammatory process. The company’s drug binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. With its revolutionary approach to attacking neurodegenerative and lung diseases, this company has the potential to change the way immunotherapies are currently conducted and may be a promising gem hiding in the biotech arena. [Learn More to See How This Undiscovered Biotech Has Blockbuster Potential With The Only Fully Human Anti-CD3 Monoclonal Antibody In Clinical Development!]( Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Tiziana Life Sciences (NASDAQ: TLSA). The compensation consists of up to $2,500 and was received/will be received from Interactive Offers. This compensation should not be considered as an endorsement of the securities of adviser Tiziana Life Sciences (NASDAQ: TLSA) and we are not responsible for any errors or omissions in any information provided about the securities of Tiziana Life Sciences (NASDAQ: TLSA) We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 4/18/24. Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe](